Abstract
Terlipressin (Glypressin), a vasopressin analog, may be administered to patients with cirrhosis receiving aβ-adrenergic antagonist. Since terlipressin alone andβ-blockers alone both decrease portal pressure, a combination of these substances may have additional portal hypotensive effects. However, the negative side effects of terlipressin may be accentuated by long-termβ-blockade. Thus, the present study examined hemodynamic and metabolic responses to terlipressin in 12 patients receiving nonselectiveβ-blockers (propranolol or nadolol). Hemodynamics and oxygen (O2) -derived variables were measured prior to and 30 min after the administration (intravenous bolus) of terlipressin (1 to 2 mg, according to body weight). The hepatic venous pressure gradient and azygos blood flow significantly decreased (from 15.3±1.1 to 12.5±1.1 mm Hg, and from 0.6±0.1 to 0.5±0.1 liters/min, respectively). Arterial and pulmonary wedged pressures significantly increased. Heart rate, cardiac index, and O2 consumption were not significantly affected by terlipressin. In conclusion, in patients with cirrhosis being treated with a nonselectiveβ-blocker, terlipressin administration decreased portal pressure. Moreover, terlipressin induced only mild systemic hemodynamic effects in these patients. These results suggest that terlipressin can be administered in patients receiving aβ-adrenergic blocker.
Similar content being viewed by others
References
Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D: Effets de la glypressine sur les circulations splanchnique et systémique des malades atteints de cirrhose. Gastroenterol Clin Biol 9:877–880, 1985
Merkel C, Gatta A, Bolognesi M, Finucci G, Battaglia G, Angeli P, Zuin R: Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 33:1103–1109, 1988
Lin HC, Tsai YT, Lee FY, Chang TT, Wang SS, Lay CS, Lee SD, Lo KJ: Systemic and portal hemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. J Hepatol 10:370–374, 1990
Moreau R, Soubrane O, Hadengue A, Sogni P, Gaudin C, Kleber G, Lebrec D: Effets hémodynamiques de l'administration de terlipressine seule ou associée à la nitroglycérine chez les malades atteints de cirrhose. Gastroenterol Clin Biol 16:680–686, 1992
Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A: Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J Hepatol 17:102–107, 1993
Moreau R, Hadengue A: Prise en charge des hémorragies digestives hautes chez les malades atteints de cirrhose.In Actualités en réanimation et urgences. Paris, Arnette, 1994, pp 55–66
Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP: The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 2:523–527, 1982
Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP: Comparison of the effects of a cardioselective and a nonselectiveβ-blocker on portal hypertension in patients with cirrhosis. Hepatology 2:528–531, 1982
Calès P, Braillon A, Girod C, Lebrec D: Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats. J Hepatol 1:349–357, 1985
Moreau R, Lee SS, Hadengue A, Ozier Y, Sicot C, Lebrec D: Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: Effects of vasoactive drugs. Hepatology 9:427–432, 1989
Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649, 1973
Valla D, Bercoff E, Menu Y, Bataille C, Lebrec D: Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology 86:1400–1403, 1984
Braillon A, Calès P, Jiron MI, Lebrec D: Estimation du débit sanguin des anastomoses porto-caves supérieures par la mesure du débit sanguin azygos chez les malades atteints de cirrhose alcoolique. Gastroenterol Clin Biol 8:47–51, 1984
Moreau R, Hadengue A, Soupison T, Mamzer MF, Kirstetter P, Saraux JL, Assous M, Roche-Sicot J, Sicot C: Arterial and mixed venous acid-base status in patients with cirrhosis. Influence of liver failure. Liver 13:20–24, 1993
Ezzat WR, Lautt WW: Hepatic arterial pressure-flow autoregulation is adenosine mediated. Am J Physiol 252:H836-H845, 1987
Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, Rodès J: Effects of alpha-adrenergic stimulation on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 4:71–79, 1987
Author information
Authors and Affiliations
Additional information
This work was supported in part by Ferring S.A.
Rights and permissions
About this article
Cite this article
Vachiery, F., Moreau, R., Gadano, A. et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectiveβ-blocker. Digest Dis Sci 41, 1722–1726 (1996). https://doi.org/10.1007/BF02088736
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02088736